Cytokine-induced memory-like (CIML) NK cells in myeloid malignancies

Current understanding

To be populated as evidence accumulates.

2026-09-01 — Type-I interferon-activated NK cells control polycythemia vera in vivo.: cross-connection with interferon-alfa: NK cells are the required effectors of type-I IFN’s anti-PV activity via TNF-α-dependent killing of JAK2V617F HSPCs — providing a mechanistic rationale for combining or sequencing IFN-α with NK-based immunotherapies (e.g., CIML NK cells) in MPN. (novelty: 5)
May 1, 202 — Mutant calreticulin–directed immunotherapies in myeloproliferative neoplasms: Review (2025) of mutant CALR-directed immunotherapy in MPN catalogs CAR-T against the mutant CALR C-terminal neoepitope as an early-stage cellular approach alongside antibodies and vaccines, without specific efficacy data. (novelty: 3)